Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Xeloda X-panding options in the adjuvant treatment of breast cancer

ASCO G.U Lawrence H. Einhorn.

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.

American Society of Clinical Oncology Endorsement of the Cancer Care Ontario (CCO) Practice Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer N Engl J Med 2011 Dec 7. Presenstor : CR 周益聖 Instructor : VS 趙大中財團法人台灣癌症臨床研究發展基金會.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Hormonally Sensitive Early-Stage Breast Cancer Current Considerations and New Directions Terry Mamounas, MD, MPH Professor of Surgery Northeastern Ohio.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

These slides were released by the speaker for internal use by Novartis.

Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.

Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.

Dubsky P et al. Proc SABCS 2012;Abstract S4-3.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy

San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Start or Switch?: Latest data from ABCSG/ARNO

Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.

Copyright © 2010, Research To Practice, All rights reserved. Current Clinical and Future Developmental Paradigms Involving Molecular Pathways in Breast.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

Anastrozole (‘Arimidex’): a new standard of care?

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.

Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.

The Effect on pCR of Bevacizumab and/or Antimetabolites Added to Standard Neoadjuvant Chemotherapy: NSABP Protocol B-40 1 Neoadjuvant Bevacizumab and Anthracycline–Taxane-Based.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Lectures inEarly Breast Cancer A PowerPoint slide set based on images from: Lectures in Early Breast Cancer Part 3: Adjuvant Therapy in Early Breast Cancer.

Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.

Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,

Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.

J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in post-menopausal.

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

Adjuvant Therapy of Breast Cancer

AROMATASE INHIBITORS.

Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*

CCO Independent Conference Coverage

EXTENDED ENDOCRINE TREATMENT IN BREAST CANCER

CCO Independent Conference Coverage

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Bergh J et al. SABCS 2009;Abstract 23.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Treatment of HR+ Breast Cancer: A Clinical Update

Julia A. Files, MD, Marcia G. Ko, MD, Sandhya Pruthi, MD

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Presentation transcript:

Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Why invite a value discussion? Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Clinically Meaningful Outcomes and Implications for Value (Ellis, et al.,J Clin Oncol Apr 20;32(12): Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Moving the Discussion to Value it’s far more than Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Seeking an Association Between Clinical Benefit, Toxicity and Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Phase III ALTTO trial The ALTTO trial did not meet its endpoints (DFS): Neither the L + T vs. T comparison nor the T → L vs. T comparison Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

E3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Presented By Lowell Schnipper at 2014 ASCO Annual Meeting